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Over the past few decades, panels of human cancer cell lines have made a signiﬁcant contribution to the
discovery and development of anticancer drugs. The National Cancer Institute 60 (NCI60), which consists
of 60 cell lines from various human cancer types, remains the most powerful human cancer cell line panel
for high throughput screening of anticancer drugs. The development of JFCR39, comprising a panel of 39
human cancer cell lines coupled with a drug-activity database, was based on NCI60. Like NCI60, JFCR39
not only provides disease-oriented information but can also predict the action mechanism or molecular
target of a given antitumor agent by utilizing the COMPARE algorithm. The molecular targets of ZSTK474
as well as several other antitumor agents have been identiﬁed by using JFCR39 and some of these com-
pounds have since entered clinical trials. In this review, we will describe human cancer cell line panels
particularly JFCR39 and its application in the discovery and/or development of anticancer drug
candidates.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Discovery and development of new anticancer drugs require a
reliable predictive preclinical model to test drug efﬁcacy. Such
models mainly include human cancer cell lines propagated in cul-
ture or as xenografts in mice, and genetically engineered mouse
models of human caricinogenesis.1 The need for high throughput
and low cost means that only the cultured human cancer cell line
model is applicable in both drug discovery and drug development.
The other models are generally used only in the drug development
process.1 Indeed, cultured human cancer cell lines have been
widely used for decades as a disease-oriented screening model
for new anticancer drugs. In the past ten years, development of
molecular-targeted anticancer drugs has been a great success
(e.g., development of imatinib). These drugs are generally designed
to target oncogene-encoding-proteins speciﬁcally or far more ex-
pressed in cancer cells. Genomic heterogeneity has been frequently
reported to exist across the patient population with the same path-
ological cancer type, and some oncogenes have been known to play
a key role in tumorigenesis. In order to match the ‘right’ drugs to
the ‘right’ patient, a predictive biomarker is required for molecu--NC-ND license.lar-targeted drugs. Cell line panels of a certain cancer type have
been used to discover these predictive biomarkers.2 As an example,
PIK3CA mutation and EGFR ampliﬁcation have been demonstrated
to be predictive biomarkers of a PI3K inhibitor GDC-0941 by use of
a large panel of breast cancer cell lines with or without PIK3CA
mutation and EGFR ampliﬁcation.2 Recently, a huge panel named
CMT1000 (Center for Molecular Therapeutics1000), which cur-
rently consists of 1200 human cancer cell lines, was established
for the development of molecular-targeted drugs against various
cancers. This panel of cell lines is expected to evaluate the sensitiv-
ity of inhibitors targeting EGFR, ERB2, MET, PDGFR, ALK and BRAF
kinases.1
NCI60 (National Cancer Institute 60),3 which was developed in
the late 1980s and consists of 60 cell lines from various human
cancer types, remains the most powerful human caner cell panel
for high throughput screening of anticancer drugs. In addition to
the disease-oriented screening of anticancer drugs, which was
the original aim for establishment of NCI60, another function of
this cancer cell line panel system is the prediction of action mech-
anism of antitumor agents. This latter function contributed to the
development of bortezomib, an inhibitor of proteasome that was
approved in 2003 by the US Food and Drug Administration
(FDA). Compared with NCI60, JFCR39 (Japanese Foundation for
Cancer Research 39) is a more compact system with a reduced
number of cell lines. Nonetheless, JFCR39 retains the functional
capability of NCI60.
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The development of JFCR39 in the early 1990s was based on the
NCI60 system with some modiﬁcation.4,5 Like NCI60, this system
consists of a human cancer cell line panel coupled with a drug-
activity database. The JFCR39 panel utilizes 30 cell lines in NCI60
together with 6 cell lines of stomach cancer of which the incidence
is high in Japan, and 3 breast cancer cell lines (HBC-4, HBC-5, and
BSY-1) established in JFCR (Japanese Foundation for Cancer
Research) (see Table 1).4,5 Genomics on each cell line of JFCR39
has been recently reported.6
Like NCI60, one important function of JFCR39 is to evaluate the
in vitro drug efﬁcacy and provide disease-oriented information
based on the differential growth inhibition activity of a certain
antitumor agent against the 39 cancer cell lines. Inhibition of cell
growth is assessed by the sulforhodamine B (SRB) assay, which
determines the change in total cellular protein of the cells follow-
ing 48 h of treatment with the antitumor agent.7–9 The molar con-
centration of the agent needed for 50% growth inhibition (GI50) of
each cell line in JFCR39 is then obtained.9,10 A graphical represen-
tation (or ‘ﬁngerprint’) for the differential growth inhibition
against the cells in the JFCR39 panel is ﬁnally plotted based on a
calculation that uses a set of GI50 values.11
Another function of the JFCR39 is to predict the action mecha-
nism or molecular target of an antitumor agent. The action mech-
anism of a drug candidate can be predicted by comparing its
ﬁngerprint with those of reference compounds (including antican-
cer drugs and chemical tools with known mechanisms) in our
drug-activity database using the COMPARE algorithm, because
the ﬁngerprint represents the whole inhibition proﬁle of the
growth-related targets in the cells.5,9 The COMPARE analysis is car-
ried out by calculating the Pearson correlation coefﬁcient (r value)
between the GI50 mean graphs of two compounds X and Y using
the following formula: r = (
P
(xi  xm) (yi  ym))/(
P
(xi  xm)2P
(yi  ym)2)1/2, where xi and yi are LogGI50 of the two compounds,
respectively, for each cell line, and xm and ym are the mean values
of xi and yi, respectively (n = 39).9,11 The r value is then used to
determine the degree of similarity, that is, the higher the r value
is, the greater the similarity of X with Y. Generally, an r value of
more than 0.6 between two agents suggests they might have a sim-
ilar action mechanism, whereas a value of >0.8 suggests they have
the same mechanism of action. Interestingly, we recently found
that the difference of r value between 0.6 and 0.8 might reﬂectTable 1
Cell lines in JFCR39 panel
Cancer Number of cell lines Cell line
Lung 7 NCI-H23, NCI-H226, NCI-H522, NCI-
H460
A549, DMS273, DMS114
Stomach 6 St-4, MKN-1, MKN-7, MKN-28,
MKN-45, MKN-74
Ovarian 5 OVCAR-3, OVCAR-4, OVCAR-5,
OVCAR-8, SK-OV-3
Renal 2 RXF-631L, ACHN
Melanoma 1 LOX-IMVI
Colon 5 HCC-2998, KM-12, HT-29
HCT-15, HCT-116
Breast 5 HBC-4, BSY-1, HBC-5
MCF-7, MDA-MB-231
Brain 6 U251, SF-268, SF-295, SF-539,
SNB-75, SNB-78
Prostate 2 DU-145, PC-3
The cell lines underlined are stomach cancer cell lines with high incidence in
Japantyped and those in italics are established in JFCR.the different target speciﬁcity between two phosphatidylinositol
3-kinase (PI3K) inhibitors.123. Application of JFCR39 in the discovery and development of
anticancer drugs
3.1. FJ5002
We have been searching for new anticancer drug candidates in
our database by using JFCR39 COMPARE analysis-guided assay. As
an example, FJ5002 (CAS number 147366-40-3, Fig. 1) was discov-
ered as a potent telomerase inhibitor in 1999.13 To search for a po-
tent telomerase inhibitor in our drug-activity database, we used
berberine, a compound which weakly inhibits telomerase with an
IC50 of 37 lM, as a seed compound. The COMPARE analysis with
JFCR39 generates a list of top 20 compounds with r values of more
than 0.6. Then we determined their telomerase inhibitory activity
and found MKT077 was a more potent telomerase inhibitor (IC50:
5 lM) than berberine. We then performed another round of COM-
PARE analysis by usingMKT077 as a seed compound. Subsequently,
another list of top 20 compounds exhibiting higher r values than 0.6
was produced. An assay of their telomerase inhibitory activity led to
the discovery of FJ5022 as a more potent telomerase inhibitor than
MKT077. FJ5002 inhibits telomerase with an IC50 of 2 lM, causes
population-doubling dependent changes characterized by progres-
sive telomere erosion, increased chromosome abnormalities and
senescence/crisis-like features in long-term cultivated U937 cells.13
3.2. Pladienolide B
The JFCR39 system can be used to determine the action mech-
anism or molecular target of an antitumor agent. Of course, predic-
tion of a molecular target depends on whether there is a reference
compound with the same molecular target in the database. If not,
we can predict that the compound has a novel molecular target,
which is different from that of current drugs or chemical tools. Pla-
dienolide B is one such example.14
Pladienolide B (see Fig. 1) is a 12-membered macrolide isolated
from Streptomyces platensis Mer-11107 by scientists of Eisai. This
compound exhibits potent growth inhibitory activity against vari-
ous cell lines including those resistant to chemotherapeutic drugs
like camptothecin, and induces cell cycle arrest at both G1 and G2/
M. Favorable in vivo antitumor activity of pladenolide B iv was also
shown on xenograft models such asWiDr and BSY-1. To investigate
the molecular target of pladienolide B, COMPARE analysis was car-
ried out by use of our JFCR39 system. However, there were no com-
pounds in our reference list with an r value greater than 0.6,
suggesting pladienolide B has a novel molecular target or mecha-
nism.14 Based on this interesting ﬁnding, continuous efforts were
made to investigate the molecular target of pladienolide B. Finally,
by use of 3H-labeled, ﬂuorescence-tagged and photoafﬁnity/biotin
(PB)-tagged chemical probes, splicing factor SF3b was demon-
strated to be the target protein of this agent.15 Currently, a deriva-
tive of pladienolide B, E7107, is under evaluation in clinical trials
for cancer treatment.
3.3. MS-247
The ﬁrst example of the use of JFCR39 to determine a molecular
target was for the synthetic compound MS-247 (see Fig. 1).9 COM-
PARE analysis predicted that this compound might target topoiso-
merase because an r value of 0.683 was shown for correlation with
CPT-11, a well known topoisomerase inhibitor. Such a prediction
was then demonstrated by the result that MS-247 inhibited the
topoisomerase-induced conversion of supercoiled DNA to nicked
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Figure 2. PI3K inhibition and antitumor activities of ZSTK474. (A) Inhibitory activity of ZSTK474 against class I PI3K isoforms. (B) In vitro antiangiogenic activity of ZSTK474.
ZSTK474 (1 lM) inhibits tube formation by HUVEC (human umbilical vein endothelial cell). Quantitative data can be seen in previous report.23 (C) In vivo antitumor efﬁcacy
of ZSTK474. Oral administration of ZSTK474 at 400 mg/kg to WiDr xenograft daily from day 0 to 26, except for days 6, 13 and 20, leads to obvious tumor growth inhibition.
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Figure 1. Chemical structures of the representative compounds identiﬁed by JFCR39.
D. Kong, T. Yamori / Bioorg. Med. Chem. 20 (2012) 1947–1951 1949DNA.9 In addition, MS-247 exhibited an average IC50 of 0.71 lM for
39 cancer cell lines as well as inducing cell cycle arrest at G2/M
phase and apoptosis at a concentration of 0.1 lM.9 Based on theseresults, MS-247 was examined for the antitumor activity and found
to exhibit potent in vivo antitumor efﬁcacy on 17 xenografts
derived from JFCR39.9
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Figure 3. Similarity between JFCR39 ﬁngerprints of PI3K inhibitors can be used to predict related target speciﬁcities. (A) Inhibition proﬁles of PI3K inhibitors ZSTK474, GDC-
0941 and NVP-BEZ235 against PI3K superfamily members. The IC50 values of the respective PI3K inhibitor for each kinase were used to plot the inhibition proﬁle, ⁄: >100.
ZSTK474 has a similar class I PI3K inhibitory speciﬁcity with GDC-0941, but different from NVP-BEZ235. (B) JFCR39 ﬁngerprints of PI3K inhibitors ZSTK474, GDC-0941 and
NVP-BEZ235. The ZSTK474 ﬁngerprint exhibits a greater similarity to the ﬁngerprint of GDC-0941, than that of NVP-BEZ235. Fingerprint indicates the differential growth
inhibition pattern of ZSTK474 for the cell lines in the JFCR39 panel. The X-axis shows the difference in logarithmic scale between the mean of LogGI50 values for all 39 cell
lines (MG-MID, expressed as 0 in the ﬁngerprint) and the LogGI50 for each cell line in the JFCR39 panel. Columns to the right of 0 indicate the sensitivity of the cell lines to a
given compound and columns to the left indicate their resistance. MG-MID = mean of LogGI50 values for all 39 cell lines; Delta = difference between the MG-MID and the
LogGI50 value for the most sensitive cell line; Range = difference between the LogGI50 values for the most resistant cell line and the most sensitive cell line.
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To date, the most successful application of JFCR39 has been the
identiﬁcation of ZSTK474 (CAS number 475110-96-4, Fig. 1) as a
PI3K inhibitor. ZSTK474 is an s-triazine derivative that was origi-
nally synthesized by Zenyaku Kogyo as an anticancer drug candi-
date.16 This compound showed the most promising antitumor
efﬁcacy among over 1500 synthesized analogues. However, the
molecular target was unknown. In 2003, growth inhibitory activity
of ZSTK474 was examined against the JFCR39 panel and its corre-
sponding ﬁngerprint was developed. COMPARE analysis was then
carried out by comparing the ﬁngerprint of ZSTK474 with those ofreference compounds in the JFCR39 drug-activity database. Inter-
estingly, a high r value of 0.766 was found between the ﬁngerprint
of ZSTK474 and that of LY294002, a well known class I PI3K inhib-
itor.17 We then predicted that ZSTK474 might also target class I
PI3K. Class I PI3K is a family of four lipid kinase isoforms that phos-
phorylate phosphatidylinositol 4,5-bisphosphate (PIP2) to generate
phosphatidylinositol 3,4,5-trisphosphate (PIP3), which plays an
important role in various processes including cell growth.18–20 To
demonstrate that ZSTK474 really targets PI3K, we investigated
the activity of the recombinant class I PI3K isoforms in the absence
or presence of ZSTK474 by use of a homogeneous time-resolved
ﬂuorescence (HTRF) assay. Our results showed that ZSTK474
D. Kong, T. Yamori / Bioorg. Med. Chem. 20 (2012) 1947–1951 1951inhibits four PI3K isoforms potently, with IC50 values of 16, 44, 5,
49 nM for PI3Ka, b, d, and c, respectively.21 (see Fig. 2A) Docking
analysis by using the crystal structure of PI3Kc-LY294002 as amod-
el suggested that ZSTK474 binds with PI3K in the ATP-binding
pocket. Lineweaver–Burk plots also indicated that ZSTK474 inhibits
PI3K by competing with ATP for a common binding site.21 In vitro,
ZSTK474 inhibited the growth of 39 human cancer cell lines with a
mean GI50 value of 0.32 lM,17 and blocked cell cycle progression at
G0/G1 phase in various human cancer cells without obvious induc-
tion of apoptosis.17,22 Moreover, ZSTK474 displayed a potent anti-
angiogenic effect via two mechanisms: (i) inhibition of HIF-1a
expression and VEGF production in cancer cells, and (ii) blockage
in the proliferation, migration, and tube formation of HUVECs
(human umbilical vein endothelial cells). (see Fig. 2B).23 Oral
administration of ZSTK474 indicated obvious in vivo antitumor efﬁ-
cacy against various cancer xenografts (see Fig. 2C) at both early
and advanced stages, without any obvious toxicity.6,22,23 Given
the favorable preclinical antitumor effect and safety, an investiga-
tional new drug application for ZSTK474 has been approved by
the US FDA and the compound is in phase I clinical trials.4
We also investigated the application of JFCR39 for prediction of
target speciﬁcity by using several PI3K inhibitors. In addition to
four class I PI3K isoforms, we determined the activities of PI3K
inhibitors ZSTK474, GDC-0941 and NVP-BEZ235 against the ki-
nases with a related structure or function (PI3K superfamily12):
PI3KC2a and PI3KC2b (class II PI3K), vacuolar protein sorting 34
(Vps34, Class III PI3K), mTOR and DNA-dependent protein kinase
(DNA-PK) (Class IV PI3K), and phosphatidylinositol 4-kinase
(PI4K). The IC50 values were calculated and used to plot the inhibi-
tion proﬁles of each inhibitor. As shown in Figure 3A, ZSTK474 and
GDC-0941 were found to be class I PI3K-speciﬁc PI3K inhibitors, by
displaying selectivity over mTOR, DNA-PK, and other PI3K super-
family members. In contrast, NVP-BEZ235 showed more potent
activity against mTOR and DNA-PK than against class I PI3Ks,12,24
suggesting the low selectivity for class I PI3K inhibition. We then
compared the JFCR39 ﬁngerprints of the three PI3K inhibitors
(see Fig. 3B). Interestingly, ZSTK474 showed a more similar ﬁnger-
print with GDC-0941 (r = 0.863), compared to that with BEZ235
(r = 0.67),12 consistent with our biochemical assay results regard-
ing inhibition of kinases belonging to the PI3K superfamily. Taken
together, these results suggest that JFCR39 can be used to predict
speciﬁcity for the molecular target of a certain antitumor agent.
Furthermore, baicalein, a natural-product PI3K inhibitor we dis-
covered from our SCADS library, also exhibits a different ﬁnger-
print to that of ZSTK474.25 Baicalein is a ﬂavonoid that inhibits
various enzymes including 12-lipoxygenase.25
We recently reported a cluster analysis of 67 anticancer com-
pounds, including PI3K/Akt/mTOR inhibitors, Mek inhibitors, and
other conventional anticancer drugs, by use of their LogGI50s for
each cell line of JFCR39,6 further supported that JFCR39 could iden-
tify anticancer compounds with various targets.
4. Conclusion
As a bioinformatics system, JFCR39 has made a signiﬁcant con-
tribution to the discovery and development of anticancer drugs. In
particular, since the JFCR39 screening system became a key part of
the program of Screening Committee of Anticancer Drugs (SCADS,funded by the Ministry of Education, Science and Culture) of
Japan,25 JFCR39 has become a well known platform for the discov-
ery of molecular-targeted anticancer drugs in Japan. Information
from the JFCR39 system has facilitated the selection of many
compounds for active development as anticancer drug candidates,
some of which have entered clinical trials (e.g., ZSTK474).4,14 The
ﬁrst molecular-targeted anticancer drug to be identiﬁed by JFCR39
is anticipated to enter the market in the near future.
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